Editorial comment: Recently developed mice with targeted disruption of the neuronal nitric oxide synthase (NOS) gene have been shown to preserve penile erections. This observation would appear to suggest that the neuronal NOS isoform derived from this gene is not essential to catalyze the generation of nitric oxide (NO) which mediates penile erection or NO is not essential for this function. Hypotheses regarding maintenance of erectile function in these mice have revolved around the availability of NO synthesized by NOS isoforms distinct from the neuronal variety and the involvement of alternative mechanisms which produce erection. This article describes the blockade of penile erection following administration of a NOS inhibitor and localizations of the endothelial NOS isoform in penile tissues of these mice. Endothelial NOS is also characterized in penises of genetically intact control mice, although it is present to a lesser extent. The implication from these ®ndings is that the endothelial NOS isoform provides a functional source of NO to regulate penile erection, possibly providing a compensatory source in neuronal NOS-de®cient transgenic animals. While this may be the case, it remains unresolved whether this isoform is exclusively compensatory in these animals and to what extent this isoform contributes to the synthesis of NO affecting erectile function in intact animals. Additional studies involving the administration of selective inhibitors of NOS isoforms may serve to elucidate their mediatory roles. Editorial comment: The phenomenon of penile erection requires cavernosal smooth muscle relaxation, likely modulated by a potassium conductance pathway operating at the cavernosal smooth muscle cell level. An interaction between this pathway and the erection effector nitric oxide (NO) represents an attractive hypothesis. This article reports that relaxant effects of NO on isolated rabbit cavernosal tissue are attenuated by a potassium channel inhibitor and hyperpolarization in rabbit cavernosal smooth muscle cells is measurably induced by NO but reversed by an inhibitor of NO production. The results indicate that NO determines penile vascular tone according to different mechanisms, dependent and independent of the in¯uence of the second messenger molecule, guanosine 3 H ,5 H -cyclic monophosphate. There is also support for the concept that cavernosal smooth muscle cells directly release NO. The action of NO in the penis appears to be preserved on multiple levels. oxide (NO), foremost of which are histochemical experiments that have localized the neuronal isoform of NO synthase (NOS). These have largely established the presence of NOS in penile nerve terminals and neuronal projection from local pelvic ganglia. However, less extensive work has been done to examine the penis-projecting NOS-containing neuronal circuitry originating at the spinal cord level which may in¯uence function of the peripheral organ. In this article, NOS is localized in preganglionic efferent and sensory afferent projections from the thoracolumbar spinal cord and in postganglionic efferent projections from the major pelvic ganglion coursing to the penis of the rat. Coexpression is con®rmed with select neuropeptides in these structures. Combined with other recent studies suggesting that NO participates in supraspinal processes, it is interesting to consider the range of control possibly exerted by this chemical on diverse neurophysiologic aspects of erectile function.
AL Burnett, MD

Diffuse veno-occlusive dysfunction: the underlying hemodynamic abnormality resulting in failure to respond to intracavernous pharmacotherapy FE Martins and H Padma-Nathan J Urol 1996; 156: 1942±1946.
Editorial comments: Although intracavernosal pharmacotherapy has emerged as a ®rst line treatment for patients with erectile dysfunction, there are signi®-cant undesirable effects, at least a 25% overall negative response rate and signi®cant drop-out rate associated with its use. Good predictors of response remain somewhat elusive and would be desirable to maximize success rates and eliminate the least appropriate candidates for this therapeutic option. In an attempt to enhance our understanding, these authors evaluated the speci®c hemodynamic abnormalities leading to non-responsiveness with intracavernosal pharmacotherapy. Sixty-nine patients with nonendocrinologic erectile dysfunction were evaluated with duplex Doppler ultrasonography and dynamic infusion cavernosometry and pharmaco-cavernosography. A quantitative analysis of the speci®c abnormalities of arterial in¯ow and veno-occlusive dysfunction were correlated with response to intracavernous injection of vaso-active drugs. Results of pharmaco-cavernosometry revealed a signi®cant difference in terms of magnitude of mean maintenance¯ow rates between the poor or no response groups (59 ml/min) and the excellent and adequate response groups (10.8 ml/min).
Those patients who had an excellent or adequate response to injection demonstrated non-visualization or focal proximal leakage on cavernosography, whereas those with a poor or no response demonstrated pan-cavernous leakage on pharmaco-cavernosography. Similarly, duplex ultrasonography revealed higher end-diastolic velocities in the poor or no response groups as compared to the better responders, re¯ecting the presence of pan-cavernous venous drainage (veno-occlusive dysfunction) in the former. Interestingly, only patients with signi®cant veno-occlusive dysfunction alone or with arteriogenic insuf®ciency responded poorly to intracavernosal therapy. No patient with pure arteriogenic dysfunction failed to respond to therapy. In fact 14% of patients with an excellent response to injection therapy were demonstrated to have pure arteriogenic insuf®ciency. Of those men with a poor or no response, 75% had combined arteriogenic and veno-occlusive dysfunction and 25% had severe veno-occlusive disease.
Hence, from this study, one can conclude that a defective corporal veno-occlusive mechanism (as a result of end-organ failure) alone or in combination with arteriogenic insuf®ciency, is the critical hemodynamic factor responsible for a less than adequate response to intracavernosal pharmacotherapy. This understanding should lead to better patient selection, decreased drop-out due to inadequate response and improve our overall success in the treatment of patients with erectile failure.
Dr LS Hakim
Positive pharmacological erection test does not rule out arteriogenic erectile dysfunction L Cormio, H Nisen, FP Selvaggi and M Ruutu J Urol 1996; 156: 1628±1630.
Editorial comments: The diagnostic reliability of pharmacologic erection testing has been brought into question for a number of reasons. The erectile response is judged subjectively and false-negative responses may occur due to anxiety and increased sympathetic response or perhaps inadequate dosing regimens. In addition, prior studies have suggested that the presence of a positive pharmacological response may still be associated with hemodynamic abnormalities. In this study, the authors tested the assumption that a positive pharmacological erection test implies normal penile vascular function. Using penile duplex Doppler studies, 205 patients were evaluated and 92 had a positive response to intracavernosal therapy with PGE1. Nine of the 92 patients (10%) with a positive response had evidence of pure arteriogenic insuf®ciency by duplex ultrasound criteria. These results con®rm those of an earlier study by Goldstein and co-workers utilizing dynamic infusion cavernosometry and cavernosography which demonstrated that a positive intracavernous injection test implies normal veno-occlusive but not necessarily normal arterial function. Hence, while a useful minimally invasive, initial screening test for patients with erectile dysfunction, the pharmacologic erection test is not completely reliable in distinguishing between vascular and non-vascular erectile dysfunction. The addition of duplex Doppler ultrasonography and/or dynamic infusion cavernosometry and cavernosography are necessary in those cases where a speci®c etiologic diagnosis is sought. Editorial comments: Over the past twenty years, the therapeutic options for men with erectile dysfunction has greatly increased. In addition, the number of men seeking care for this urologic disease is ever increasing, due to improved physician and patient awareness and technological advances in the diagnosis and treatment of erectile dysfunction. The speci®c advantages and disadvantages of each therapy must be discussed with the patient and, if possible, the partner prior to instituting treatment. The ef®cacy of oral therapy with yohimbine has been shown to be marginal at best and is not recommended. With regard to arterial and venous reconstructive surgery, arterial revascularization remains a viable option in men with normal venoocclusive function and arteriogenic insuf®ciency due to pelvic or perineal trauma. Ideally, this should be performed in an academic setting with long-term follow-up available. Of note, newer treatment options, including intraurethral PGE1 were not able to be evaluated due to the format and timing of this study. The panel also discussed the need for improved and standardized methods for evaluation of erectile dysfunction. In addition, the need for better design of future studies, including standardization of reporting outcomes, which can ideally be applied uniformly to patients treated with different modalities was emphasized. That the`ideal' therapy does not yet exist reinforces the need for continued improvement of currently available therapeutic modalities and expansion of future research activities.
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